Vitamin D and multiple sclerosis: Where do we go from here?

Expert Review of Neurotherapeutics

Volumn 14, Issue 1, 2014, Pages 9-18

  Salzer, Jonatan ^a   Biström, Martin ^a   Sundström, Peter ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

Multiple sclerosis; Primary prevention; Prospective biobank studies; Randomized controlled trials; Ultraviolet B (UVB) radiation; Vitamin D

Indexed keywords

BETA1A INTERFERON; COLECALCIFEROL; PLACEBO; VITAMIN D;

HUMAN; LOSS OF FUNCTION MUTATION; LOW DRUG DOSE; MULTIPLE SCLEROSIS; PATHOPHYSIOLOGY; PRIMARY PREVENTION; REVIEW; ULTRAVIOLET B RADIATION; VITAMIN BLOOD LEVEL; VITAMIN D RESPONSIVE ELEMENT; VITAMIN METABOLISM;

HUMANS; MULTIPLE SCLEROSIS; VITAMIN D;

EID: 84893083577     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2014.864952     Document Type: Review

References (75)

1. Noseworthy JH, Lucchinetti C, RodriguezM, Weinshenker BG. Multiple sclerosis. N. Engl. J. Med. 343(13), 938-952 (2000
2. Ascherio A, Munger KL, Lunemann JD. The initiation and prevention of multiple sclerosis. Nat. Rev. Neurol. 8(11), 602-612 (2012
3. Sawcer S, Hellenthal G, Pirinen M et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476(7359), 214-219 (2011
4. Beecham AH, Patsopoulos NA, Xifara DK et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat. Genet. 45, 1353-1360 (2013
5. Sundstrom P, Salzer J. Vitamin D and multiple sclerosis: Timing of sampling, treatment and prevention. Biomark. Med. 7(2), 193-195 (2013
6. Handel AE, Giovannoni G, Ebers GC, Ramagopalan SV. Environmental factors and their timing in adult-onset multiple sclerosis. Nat. Rev. Neurol. 6(3), 156-166 (2010
7. Holick MF. Vitamin D deficiency. N. Engl. J. Med. 357(3), 266-281 (2007
8. Thompson PD, Jurutka PW, Haussler CA, Whitfield GK, Haussler MR. Heterodimeric DNA binding by the vitamin D receptor and retinoid X receptors is enhanced by 1,25-dihydroxyvitamin D3 and inhibited by 9-cis-retinoic acid. Evidence for allosteric receptor interactions. J. Biol. Chem. 273(14), 8483-8491 (1998
9. Jimenez-Lara AM, Aranda A. Interaction of vitamin D and retinoid receptors on regulation of gene expression. Horm. Res. 54(5-6), 301-305 (2000
10. Mora JR, Iwata M, Von Andrian UH. Vitamin effects on the immune system: Vitamins A and D take centre stage. Nat. Rev. Immunol. 8(9), 685-698 (2008
11. Reid IR, Bolland MJ, Grey A. Effects of vitamin D supplements on bone mineral density: A systematic review and meta-analysis. Lancet doi:10.1016/S0140- 6736(13)61647-5 (2013) (Epub ahead of print
12. Salzer J, Hallmans G, Nystrom M, Stenlund H, Wadell G, Sundstrom P. Vitamin D as a protective factor in multiple sclerosis. Neurology 79(21), 2140-2145 (2012). which showed that subjects with serum 25(OH)D levels ‡75 nmol/l had a lower risk of MS than subjects with lower levels, and that levels of 25(OH)D had decreased in the population since the 1970
13. Salzer J, Hallmans G, Nystrom M, Stenlund H, Wadell G, Sundstrom P. Vitamin A and systemic inflammation as protective factors in multiple sclerosis. Mult. Scler. 19(8), 1046-1051 (2013
14. Hart PH, Gorman S, Finlay-Jones JJ. Modulation of the immune system by UV radiation: More than just the effects of vitamin D Nat. Rev. Immunol. 11(9), 584-596 (2011). including didactic illustrations
15. Smolders J, Damoiseaux J, Menheere P, Hupperts R. Vitamin D as an immune modulator in multiple sclerosis, a review. J. Neuroimmunol. 194(1-2), 7-17 (2008
16. Shaw NJ, Mughal MZ. Vitamin D and child health part 1 (skeletal aspects). Arch. Dis. Child. 98(5), 363-367 (2013
17. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 296(23), 2832-2838 (2006). 25 hydroxyvitamin D (25[OH]D) levels ‡100 nmol/l had a lower risk for MS than subjects with levels <63 nmol/l.
18. Simpson S Jr, Taylor B, Blizzard L et al. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann. Neurol. 68(2), 193-203 (2010
19. IOM (Institute of Medicine). Dietary Reference Intakes for Calcium and Vitamin D. The National Academies Press, Washington DC, USA (2011
20. Holick MF, Binkley NC, Bischoff-Ferrari HA et al. Evaluation, treatment, and prevention of vitamin D deficiency: An Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96(7), 1911-1930 (2011
21. Brannon PM, Yetley EA, Bailey RL, Picciano MF. Overview of the conference "Vitamin D and Health in the 21st Century: An Update". Am. J. Clin. Nutr. 88(2), 483S-490S (2008
22. Saltyte Benth J, Myhr KM, Loken-Amsrud KI et al. Modelling and prediction of 25-hydroxyvitamin D levels in Norwegian relapsing-remitting multiple sclerosis patients. Neuroepidemiology 39(2), 84-93 (2012
23. Grant WB. Critique of the U-shaped serum 25-hydroxyvitamin D level-disease response relation. Dermatoendocrinol. 1(6), 289-293 (2009
24. Tuohimaa P, Tenkanen L, Ahonen M et al. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: A longitudinal, nested case-control study in the Nordic countries. Int. J. Cancer 108(1), 104-108 (2004
25. Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch. Intern. Med. 168(15), 1629-1637 (2008
26. Wang TJ, Pencina MJ, Booth SL et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 117(4), 503-511 (2008
27. Durup D, Jorgensen HL, Christensen J, Schwarz P, Heegaard AM, Lind B. A reverse J-shaped association of all-cause mortality with serum 25-hydroxyvitamin D in general practice: The CopD study. J. Clin. Endocrinol. Metab. 97(8), 2644-2652 (2012
28. Michaelsson K, Baron JA, Snellman G et al. Plasma vitamin D and mortality in older men: A community-based prospective cohort study. Am. J. Clin. Nutr. 92(4), 841-848 (2010
29. Jenab M, Bueno-De-Mesquita HB, Ferrari P et al. Association between pre-diagnostic circulating vitamin D concentration and risk of colorectal cancer in European populations:a nested case-control study. BMJ 340, b5500 (2010
30. Brondum-Jacobsen P, Nordestgaard BG, Schnohr P, Benn M. 25-Hydroxyvitamin D and symptomatic ischemic stroke: An original study and meta-analysis. Ann. Neurol. 73(1), 38-47 (2013
31. Webb AR, Kline L, Holick MF. Influence of season and latitude on the cutaneous synthesis of vitamin D3: Exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J. Clin. Endocrinol. Metab. 67(2), 373-378 (1988
32. Manson JE, Bassuk SS, Lee IM et al. The VITamin D and OmegA-3 TriaL (VITAL): Rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp. Clin. Trials 33(1), 159-171 (2012
33. Koch-Henriksen N, Sorensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol. 9(5), 520-532 (2011
34. Sloka S, Silva C, Pryse-Phillips W, Patten S, Metz L, Yong VW. A quantitative analysis of suspected environmental causes of MS. Can. J. Neurol. Sci. 38(1), 98-105 (2011
35. studies and satellite-derived ultraviolet B (UVB) radiation data to show that UVB intensity was a 20-times better predictor of MS prevalence than latitude. 35 Gale CR, Martyn CN. Migrant studies in multiple sclerosis. Prog. Neurobiol. 47(4-5), 425-448 (1995
36. Lucas RM, Ponsonby AL, Dear K et al. Sun exposure and vitamin D are independent risk factors for CNS demyelination. Neurology 76(6), 540-548 (2011
37. Ascherio A, Munger KL, Giovannucci E. Sun exposure and vitamin D are independent risk factors for CNS demyelination. Neurology 77(14), 1405, author reply 1405-1406 (2011
38. Vimaleswaran KS, Berry DJ, Lu C et al. Causal relationship between obesity and vitamin D status: Bi-directional Mendelian randomization analysis of multiple cohorts. PLoS Med. 10(2), e1001383 (2013
39. Brot C, Jorgensen NR, Sorensen OH. The influence of smoking on vitamin D status and calcium metabolism. Eur. J. Clin. Nutr. 53(12), 920-926 (1999
40. Hedstrom AK, Olsson T, Alfredsson L. High body mass index before age 20 is associated with increased risk for multiple sclerosis in both men and women. Mult. Scler. 18(9), 1334-1336 (2012
41. Salzer J, Hallmans G, Nystrom M, Stenlund H, Wadell G, Sundstrom P. Smoking as a risk factor for multiple sclerosis. Mult. Scler. 19(8), 1022-1027 (2013
42. Schwarz A, Navid F, Sparwasser T, Clausen BE, Schwarz T. 1,25-dihydroxyvitamin D exerts similar immunosuppressive effects as UVR but is dispensable for local UVR-induced immunosuppression. J. Invest. Dermatol. 132(12), 2762-2769 (2012
43. Mcloone P, Simics E, Barton A, Norval M, Gibbs NK. An action spectrum for the production of cis-urocanic acid in human skin in vivo. J. Invest. Dermatol. 124(5), 1071-1074 (2005
44. Kammeyer A, Pavel S, Asghar SS, Bos JD, Teunissen MB. Prolonged increase of cis-urocanic acid levels in human skin and urine after single total-body ultraviolet exposures. Photochem. Photobiol. 65(3), 593-598 (1997
45. Moodycliffe AM, Norval M, Kimber I, Simpson TJ. Characterization of a monoclonal antibody to cis-urocanic acid: Detection of cis-urocanic acid in the serum of irradiated mice by immunoassay. Immunology 79(4), 667-672 (1993
46. Correale J, Farez MF. Modulation of multiple sclerosis by sunlight exposure: Role of cis-urocanic acid. J. Neuroimmunol 261(1-2), 134-140 (2013
47. Holmoy T, Moen SM, Gundersen TA et al. 25-hydroxyvitamin D in cerebrospinal fluid during relapse and remission of multiple sclerosis. Mult. Scler. 15(11), 1280-1285 (2009
48. Ramagopalan SV, Dyment DA, Cader MZ et al. Rare variants in the CYP27B1 gene are associated with multiple sclerosis. Ann. Neurol. 70(6), 881-886 (2011
49. Barizzone N, Pauwels I, Luciano B et al. No evidence for a role of rare CYP27B1 functional variations in multiple sclerosis. Ann. Neurol. 73(3), 433-437 (2013
50. Reinthaler E, Machetanz G, Hotzy C et al. No evidence for a role of rare CYP27B1 variants in Austrian multiple sclerosis patients. Mult. Scler. doi:10.1177/1352458513498130 (2013) (Epub ahead of print
51. Ban M, Caillier S, Mero IL et al. No evidence of association between mutant alleles of the CYP27B1 gene and multiple sclerosis. Ann. Neurol. 73(3), 430-432 (2013
52. Wang TJ, Zhang F, Richards JB et al. Common genetic determinants of vitamin D insufficiency: A genome-wide association study. Lancet 376(9736), 180-188 (2010
53. Ahn J, Yu K, Stolzenberg-Solomon R et al. Genome-wide association study of circulating vitamin D levels. Hum. Mol. Genet. 19(13), 2739-2745 (2010
54. Disanto G, Sandve GK, Berlanga-Taylor AJ et al. Vitamin D receptor binding, chromatin states and association with multiple sclerosis. Hum. Mol. Genet. 21(16), 3575-3586 (2012
55. Ramagopalan SV, Maugeri NJ, Handunnetthi L et al. Expression of the multiple sclerosis-associated MHC class II Allele HLA-DRB1.1501 is regulated by vitamin D. PLoS Genet. 5(2), e1000369 (2009
56. Smith GD, Ebrahim S. 'Mendelian randomization': Can genetic epidemiology contribute to understanding environmental determinants of disease? Int. J. Epidemiol. 32(1), 1-22 (2003
57. Munger KL, Zhang SM, O'reilly E et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 62(1), 60-65 (2004
58. Hypponen E, Laara E, Reunanen A, Jarvelin MR, Virtanen SM. Intake of vitamin D and risk of type 1 diabetes: A birth-cohort study. Lancet 358(9292), 1500-1503 (2001
59. Tremlett H, Van Der Mei IA, Pittas F et al. Monthly ambient sunlight, infections and relapse rates in multiple sclerosis. Neuroepidemiology 31(4), 271-279 (2008
60. Mowry EM, Waubant E, Mcculloch CE et al. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann. Neurol. 72(2), 234-240 (2012
61. Mosayebi G, Ghazavi A, Ghasami K, Jand Y, Kokhaei P. Therapeutic effect of vitamin D3 in multiple sclerosis patients. Immunol. Invest. 40(6), 627-639 (2011
62. Stein MS, Liu Y, Gray OM et al. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology 77(17), 1611-1618 (2011
63. Kampman MT, Steffensen LH, Mellgren SI, Jorgensen L. Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: Exploratory outcomes from a double-blind randomised controlled trial. Mult. Scler. 18(8), 1144-1151 (2012
64. Soilu-Hanninen M, Aivo J, Lindstrom BM et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 83(5), 565-571 (2012
65. Shaygannejad V, Janghorbani M, Ashtari F, Dehghan H. Effects of adjunct low-dose vitamin d on relapsing-remitting multiple sclerosis progression: Preliminary findings of a randomized placebo-controlled trial. Mult. Scler. Int. 2012, 452541 (2012
66. Pozuelo-Moyano B, Benito-Leon J, Mitchell AJ, Hernandez-Gallego J. A systematic review of randomized, doubleblind, placebo-controlled trials examining the clinical efficacy of vitamin D in multiple sclerosis. Neuroepidemiology 40(3), 147-153 (2012
67. Smolders J, Hupperts R, Barkhof F et al. Efficacy of vitamin D(3) as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: A Phase II, multicenter, double-blind, randomized, placebo-controlled trial. J. Neurol. Sci. 311(1-2), 44-49 (2011
68. Dorr J, Ohlraun S, Skarabis H, Paul F. Efficacy of vitamin D supplementation in multiple sclerosis (EVIDIMS Trial): Study protocol for a randomized controlled trial. Trials 13, 15 (2012
69. O Connel K, Kelly S, Kinsella K et al. Dose-related effects of vitamin D on immune responses in patients with clinically isolated syndrome and healthy control participants: Study protocol for an exploratory randomized double-blind placebo-controlled trial. Trials 14(1), 272 (2013
70. Vukusic S, Hutchinson M, Hours M et al. Pregnancy and multiple sclerosis (the PRIMS study): Clinical predictors of post-partum relapse. Brain 127(Pt 6), 1353-1360 (2004
71. Ghezzi A, Annovazzi P, Portaccio E, Cesari E, Amato MP. Current recommendations for multiple sclerosis treatment in pregnancy and puerperium. Expert Rev. Clin. Immunol. 9(7), 683-692 (2013
72. Manaseki-Holland S, Maroof Z, Bruce J et al. Effect on the incidence of pneumonia of vitamin D supplementation by quarterly bolus dose to infants in Kabul: A randomised controlled superiority trial. Lancet 379(9824), 1419-1427 (2012
73. Murdoch DR, Slow S, Chambers ST et al. Effect of vitamin D3 supplementation on upper respiratory tract infections in healthy adults: The VIDARIS randomized controlled trial. JAMA 308(13), 1333-1339 (2012
74. Mcalindon T, Lavalley M, Schneider E et al. Effect of vitamin D supplementation on progression of knee pain and cartilage volume loss in patients with symptomatic osteoarthritis: A randomized controlled trial. JAMA 309(2), 155-162 (2013
75. Witham MD, Price RJ, Struthers AD et al. Cholecalciferol treatment to reduce blood pressure in older patients with isolated systolic hypertension: The vitdish randomized controlled trial. JAMA Intern. Med. doi:10.1001/ jamainternmed.2013.9043 (2013) (Epub ahead of print